BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 21788720)

  • 1. [Tinea unguium].
    Harada T
    Med Mycol J; 2011; 52(2):77-95. PubMed ID: 21788720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathogenic Dermatophytes Survive in Nail Lesions During Oral Terbinafine Treatment for Tinea Unguium.
    Iwanaga T; Ushigami T; Anzawa K; Mochizuki T
    Mycopathologia; 2017 Aug; 182(7-8):673-679. PubMed ID: 28281037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Terbinafine: a review of its use in onychomycosis in adults.
    Darkes MJ; Scott LJ; Goa KL
    Am J Clin Dermatol; 2003; 4(1):39-65. PubMed ID: 12477372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tinea Unguium: Diagnosis and Treatment in Practice.
    Asz-Sigall D; Tosti A; Arenas R
    Mycopathologia; 2017 Feb; 182(1-2):95-100. PubMed ID: 27787643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of toenail onychomycosis.
    Tom CM; Kane MP
    Am J Health Syst Pharm; 1999 May; 56(9):865-71. PubMed ID: 10344609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of onychomycosis in children.
    Gupta AK; De Rosso JQ
    Postgrad Med; 1999 Jul; Spec No():31-7. PubMed ID: 10492664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging drugs for the treatment of onychomycosis.
    Gupta AK; Stec N
    Expert Opin Emerg Drugs; 2019 Dec; 24(4):213-220. PubMed ID: 31652088
    [No Abstract]   [Full Text] [Related]  

  • 8. Onychomycosis--treatment, relapse and re-infection.
    Hull PR
    Dermatology; 1997; 194 Suppl 1():7-9. PubMed ID: 9154393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Itraconazole and terbinafine in perspective. From petri dish to patient.
    De Doncker P; Gupta AK
    Postgrad Med; 1999 Jul; Spec No():6-11. PubMed ID: 10492660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-blind, randomized, prospective study on terbinafine and itraconazole for treatment of dermatophyte toenail onychomycosis in the elderly.
    Gupta AK; Konnikov N; Lynde CW
    J Am Acad Dermatol; 2001 Mar; 44(3):479-84. PubMed ID: 11209118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous terbinafine and pulse itraconazole for the treatment of non-dermatophyte mold toenail onychomycosis.
    Shemer A; Gupta AK; Kamshov S; Babaev M; Hermush V; Farhi R; Daniel CR; Foley KA
    J Dermatolog Treat; 2021 May; 32(3):310-313. PubMed ID: 31415182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Terbinafine for the treatment of pedal onychomycosis. A foot closer to the promised land of cured nails?
    Shear NH; Gupta AK
    Arch Dermatol; 1995 Aug; 131(8):937-42. PubMed ID: 7632066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ultrastructural changes of Trichophyton rubrum in tinea unguium after itraconazole therapy in vivo observed using scanning electron microscopy.
    Yue X; Wang A; Sun Y; Li Q
    Clin Exp Dermatol; 2018 Dec; 43(8):883-889. PubMed ID: 30387190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antimycotic therapy of Tinea unguium and other onychomycoses].
    Stock I
    Med Monatsschr Pharm; 2009 Aug; 32(8):289-98; quiz 299-300. PubMed ID: 19777736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Diagnosis of non dermatophyte onychomycosis ant its relevance for treatment].
    Monod M; Lurati M; Baudraz-Rosselet F
    Rev Med Suisse; 2013 Apr; 9(380):730-3. PubMed ID: 23621043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current topics in diagnosis and treatment of tinea unguium in Japan.
    Tanuma H
    J Dermatol; 1999 Feb; 26(2):87-97. PubMed ID: 10091478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro antifungal susceptibility patterns of dermatophyte strains causing tinea unguium.
    Sarifakioglu E; Seçkin D; Demirbilek M; Can F
    Clin Exp Dermatol; 2007 Nov; 32(6):675-9. PubMed ID: 17714532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Onychomycosis insensitive to systemic terbinafine and azole treatments reveals non-dermatophyte moulds as infectious agents.
    Baudraz-Rosselet F; Ruffieux C; Lurati M; Bontems O; Monod M
    Dermatology; 2010; 220(2):164-8. PubMed ID: 20110639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Causative pathogens in onychomycosis and the possibility of treatment resistance: a review.
    Evans EG
    J Am Acad Dermatol; 1998 May; 38(5 Pt 3):S32-36. PubMed ID: 9594934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis.
    Gupta AK; Shear NH
    Drug Saf; 2000 Jan; 22(1):33-52. PubMed ID: 10647975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.